From: Cost and cost-effectiveness of tuberculosis treatment shortening: a model-based analysis
 | South Africa | Brazil | Bangladesh | Tanzania | reference |
---|---|---|---|---|---|
All scenarios | |||||
 GeneXpert coverage in new patients | 100% | 100% | 0% | 0% | assumption |
 GeneXpert coverage in previously treated | 100% | 100% | 100% | 100% | assumption |
Guidelines | |||||
 ART if HIV/TB | 100% | 100% | 100% | 100% | |
 MDR treatment | 100% | 100% | 100% | 100% | |
 Default rate | 1–2% | 1–2% | 1–2% | 1–2% | [4] |
Current | |||||
 ART if HIV/TB | 66% | 54.7% | 100% | 73% | |
 MDR treatment | 60% | 44.5% | 15.4% | 12.3% | |
 Default rate | 8% [6–10] | 21% [19–23] | 2% [1.8–2.2] | 3% [2–4] | [1] |